These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17432824)

  • 1. Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels.
    Smith JD; Chen A; Ernst LA; Waggoner AS; Campbell PG
    Bioconjug Chem; 2007; 18(3):695-701. PubMed ID: 17432824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin.
    Ray MJ; Marsh NA
    Thromb Haemost; 1997 Sep; 78(3):1021-6. PubMed ID: 9308747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of fibrinogen isolation for manufacturing autologous fibrin glue for use as scaffold in tissue engineering.
    Froelich K; Pueschel RC; Birner M; Kindermann J; Hackenberg S; Kleinsasser NH; Hagen R; Staudenmaier R
    Artif Cells Blood Substit Immobil Biotechnol; 2010 May; 38(3):143-9. PubMed ID: 20367549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Kunitz-type protease inhibitor engineered for enhanced matrix retention extends longevity of fibrin biomaterials.
    Briquez PS; Lorentz KM; Larsson HM; Frey P; Hubbell JA
    Biomaterials; 2017 Aug; 135():1-9. PubMed ID: 28477492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered aprotinin for improved stability of fibrin biomaterials.
    Lorentz KM; Kontos S; Frey P; Hubbell JA
    Biomaterials; 2011 Jan; 32(2):430-8. PubMed ID: 20864171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipose precursor cells (preadipocytes) induce formation of new vessels in fibrin glue on the newly developed cylinder chorioallantoic membrane model (CAM).
    Borges J; Torío-Padrón N; Momeni A; Mueller MC; Tegtmeier FT; Stark BG
    Minim Invasive Ther Allied Technol; 2006; 15(4):246-52. PubMed ID: 16966139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrin degradation products. A review of structures found in vitro and in vivo.
    Gaffney PJ
    Ann N Y Acad Sci; 2001; 936():594-610. PubMed ID: 11460518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa.
    Schense JC; Hubbell JA
    Bioconjug Chem; 1999; 10(1):75-81. PubMed ID: 9893967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tranexamic acid--an alternative to aprotinin in fibrin-based cardiovascular tissue engineering.
    Cholewinski E; Dietrich M; Flanagan TC; Schmitz-Rode T; Jockenhoevel S
    Tissue Eng Part A; 2009 Nov; 15(11):3645-53. PubMed ID: 19496679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Textilinin-1, an alternative anti-bleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss.
    Flight SM; Johnson LA; Du QS; Warner RL; Trabi M; Gaffney PJ; Lavin MF; de Jersey J; Masci PP
    Br J Haematol; 2009 Apr; 145(2):207-11. PubMed ID: 19236611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composition of fibrin glues significantly influences axial vascularization and degradation in isolation chamber model.
    Arkudas A; Pryymachuk G; Hoereth T; Beier JP; Polykandriotis E; Bleiziffer O; Gulle H; Horch RE; Kneser U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):419-27. PubMed ID: 22576289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
    Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M
    J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using a Radial Diffusion Method to Investigate the Role of Plasmin Degradation of Fibrin in a Physical Model of an Early-phase Wound.
    Chukwuemeka CP; Cupp J; Sanders JR
    Wounds; 2017 Apr; 29(4):115-121. PubMed ID: 28135202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin-based tissue-engineered blood vessels: differential effects of biomaterial and culture parameters on mechanical strength and vascular reactivity.
    Yao L; Swartz DD; Gugino SF; Russell JA; Andreadis ST
    Tissue Eng; 2005; 11(7-8):991-1003. PubMed ID: 16144435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The control of fibrogenesis: stimulation and suppression of collagen synthesis in the chick chorioallantoic membrane with fibrin degradation products, wound extracts and proteases.
    Thompson WD; Evans AT; Campbell R
    J Pathol; 1986 Mar; 148(3):207-15. PubMed ID: 3009765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial exudate: stimulation of cell proliferation by plasma not serum is associated with fibrinolysis.
    Stirk CM; Thompson WD
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):537-41. PubMed ID: 2133231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of conformational domain lability of fibrinogen molecule in the processes of fibrin formation and fibrinolysis.
    Rozenfel'd MA; Leonova VB; Biryukova MI
    Dokl Biochem Biophys; 2006; 408():165-8. PubMed ID: 16913421
    [No Abstract]   [Full Text] [Related]  

  • 19. Fibronectin and fibrinolysis are not required for fibrin gel contraction by human skin fibroblasts.
    Tuan TL; Grinnell F
    J Cell Physiol; 1989 Sep; 140(3):577-83. PubMed ID: 2476450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of "aging" of fibrinogen molecule on the structure and properties of fibrin gel].
    Rozenfel'd MA; Leonova VB; Biriukova MI
    Izv Akad Nauk Ser Biol; 2007; (4):394-401. PubMed ID: 17966900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.